Authors
Maria Pokorska-Śpiewak, Ewa Talarek, Małgorzata Aniszewska, Anna Dobrzeniecka, Magdalena M Marczyńska
Published in
Clinical and experimental hepatology. Volume 12. Issue 2. Pages 114-120. Epub Jun 30, 2026.
Abstract
The objective of this review was to summarize previous Polish experience in treating hepatitis C virus (HCV) in children with direct-acting antivirals (DAAs) and to describe the current situation and perspectives for future HCV treatment in the pediatric cohort. Children aged at least 3 years were only included in the national Polish therapeutic HCV program on April 1, 2025. However, since 2018, over 200 children and adolescents have been treated with DAAs in noncommercial and commercial trials and real-life programs. Through the current therapeutic program, only adult dosages and formulations of DAAs are available; thus, younger children may not be included. They may, however, receive pediatric formulations donated courtesy of pharmaceutical companies. Screening programs, at least for children at risk of HCV infection, should be implemented to identify candidates for DAA treatment.
PMID:
42724535
Bibliographic data and abstract were imported from PubMed on 11 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0